Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249912 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia
A Phase 3 study of Hypercholesterolemia, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 415
- Enrollment target
- 20
- Study locations
NCT00249912 is a Phase 3 study of Hypercholesterolemia that has completed, run by Takeda. The registered enrollment target is 415 participants, below the 810-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT00249912, a Phase 3 study of Hypercholesterolemia, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 415 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with rosuvastatin on cholesterol levels in treating patients with elevated cholesterol.
Conditions Studied
Interventions
- DRUG Rosuvastatin
- DRUG Lapaquistat acetate and rosuvastatin
Study Locations (20)
California
- - Long Beach
- - Mission Viejo
- - Orange
- - Redondo Beach
- - Rolling Hills Estates
- - San Diego
- - Torrance
- - Tustin
Florida
- - DeLand
- - Fort Lauderdale
- - Hialeah
- - Jacksonville
- - Jupiter
- - Melbourne
Alabama
- - Birmingham
- - Haleyville
- - Mobile
Connecticut
- - Avon
- - Bristol
Arizona
- - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 415 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00249912
The ClinicalTrials.gov registry entry for NCT00249912 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 415 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 810-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (49% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 2 interventions - of which Rosuvastatin is the first listed.
NCT00249912 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00249912 about?
NCT00249912 is a clinical study titled "Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia". The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with rosuvastatin on cholesterol levels in treating patients with elevated cholesterol.
What is the current status of trial NCT00249912?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 415 participants. The study started on 2005-10. Estimated completion is 2007-04.
What conditions does trial NCT00249912 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
What interventions are being tested in trial NCT00249912?
The interventions under investigation include: Rosuvastatin (DRUG), Lapaquistat acetate and rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT00249912?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00249912 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
ACTIVE NOT RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
COMPLETED · Phase 3
-
Actual Use Trial of Atorvastatin Calcium 10 mg
COMPLETED · Phase 3
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.